Soon after its discovery in 1976 (1), immuno-oncologists recognized the potential for IL2 as a cancer therapy given its ability to generate “lymphokine-activated killer cells”, later identified as CD8+ T effector and NK cells (2). The gene discussed is IL2; the disease is cancer.